Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Return on Equity (2016 - 2026)

Heron Therapeutics filings provide 15 years of Return on Equity readings, the most recent being 0.01% for Q1 2026.

  • On a quarterly basis, Return on Equity fell 1.0% to 0.01% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.01%, a 1.0% decrease, with the full-year FY2025 number at 0.01%, up 1.0% from a year prior.
  • Return on Equity hit 0.01% in Q1 2026 for Heron Therapeutics, down from 0.0% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.05% in Q2 2023 to a low of 5.82% in Q3 2022.
  • Median Return on Equity over the past 5 years was 0.0% (2025), compared with a mean of 0.54%.
  • Biggest five-year swings in Return on Equity: plummeted -581bps in 2022 and later skyrocketed 586bps in 2023.
  • Heron Therapeutics' Return on Equity stood at 0.1% in 2022, then skyrocketed by 137bps to 0.04% in 2023, then plummeted by -91bps to 0.0% in 2024, then crashed by -156bps to 0.0% in 2025, then plummeted by -413bps to 0.01% in 2026.
  • The last three reported values for Return on Equity were 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025) per Business Quant data.